Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 79, Issue 1, pp 173–180 | Cite as

Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma

  • Ji Young Lee
  • Cheryn Song
  • Bum Sik Hong
  • Jun Hyuk Hong
  • Hanjong Ahn
  • Jae Lyun LeeEmail author
Original Article
  • 229 Downloads

Abstract

Purpose

The standard regimen of high-dose interleukin-2 (HDIL-2) for metastatic renal cell carcinoma (RCC) is two cycles separated by 9 days, which constitutes one course. Each course is separated by an 8–12 weeks. However, the 9-day interval between each HDIL-2 cycle is often not long enough to allow recovery from adverse effects. Therefore, we modified HDIL-2 schedules by increasing the interval between each cycle without changing the total cumulative doses of IL-2.

Methods

Clinical data from 37 patients who were treated with modified HDIL-2 schedule were reviewed. Patients received the first dose of IL-2 on day 1 and took subsequent doses every 8 h for a maximum of 14 doses each cycle. Treatment was repeated every 4 weeks, and a maximum of six cycles were planned.

Results

The overall response rate was 35% including two patients with complete response. With a median follow-up duration of 46.9 months, median progression-free survival was 16.0 months (95% CI 10.2–21.7 months) and median overall survival was 58.9 months (95% CI 49.6–68.3 months) with a 3-year overall survival rate of 77.8%. Toxicity profile was acceptable and comparable to standard HDIL-2 schedule. There were no treatment-related mortalities. The incidence of ≥grade 3 adverse events did not differ between patients who had prior exposure to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) and VEGFR TKI-naïve patients.

Conclusion

Modified HDIL-2 schedule seems to be a safe and effective option for selected Asian patients with metastatic RCC, even in patients with prior VEGFR TKI treatment.

Keywords

Renal cell carcinoma Immunotherapy Interleukin-2 Modified regimen 

Notes

Acknowledgements

This study was presented in part at the 7th European Multidisciplinary Meeting on Urological Cancers, November 12–15, 2015, Barcelona, Spain.

Compliance with ethical standards

Conflict of interest

JL Lee received speaker honoraria from Astellas, Novartis, and Pfizer, and research funding from Bayer, Exelixis, Janssen, Novartis, and Pfizer. JY Lee, C Song, BS Hong, JH Hong, and H Ahn declare that they had no conflict of interest.

Funding

This study was supported by a Grant (HI12C1788, HI14C1061, HI14C1931, HI14C1731) from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Korea.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the Institutional Review Board of Asan Medical Center and with the 1964 Helsinki Declaration and its later amendments. For retrospective design of the current study formal informed consent was not required.

References

  1. 1.
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696PubMedGoogle Scholar
  2. 2.
    Schwartzentruber DJ (2001) Guidelines for the safe administration of high-dose interleukin-2. J Immunother 24(4):287–293CrossRefPubMedGoogle Scholar
  3. 3.
    Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS (2013) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19(14):3936–3943. doi: 10.1158/1078-0432.CCR-13-0895 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A (2003) Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98(12):2566–2575. doi: 10.1002/cncr.11851 CrossRefPubMedGoogle Scholar
  5. 5.
    Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM (1988) Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318(24):1557–1563. doi: 10.1056/NEJM198806163182401 CrossRefPubMedGoogle Scholar
  6. 6.
    Royal RE, Steinberg SM, Krouse RS, Heywood G, White DE, Hwu P, Marincola FM, Parkinson DR, Schwartzentruber DJ, Topalian SL, Yang JC, Rosenberg SA (1996) Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 2(2):91–98PubMedGoogle Scholar
  7. 7.
    West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316(15):898–905. doi: 10.1056/NEJM198704093161502 CrossRefPubMedGoogle Scholar
  8. 8.
    Clark J, Morse MA, Wong MKK, McDermott D, Kaufman H, Daniels GA, Pemitt JC, Hua H, Aung S (2016) Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2). J Clin Oncol 34(suppl 2S):abstr 511Google Scholar
  9. 9.
    McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB (2015) The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21(3):561–568. doi: 10.1158/1078-0432.CCR-14-1520 CrossRefPubMedGoogle Scholar
  10. 10.
    Park I, Cho YM, Lee JL, Ahn JH, Lee DH, Song C, Hong JH, Kim CS, Ahn H (2013) Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component. J Cancer Res Clin Oncol 139(5):817–827. doi: 10.1007/s00432-013-1386-4 CrossRefPubMedGoogle Scholar
  11. 11.
    Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892. doi: 10.1056/NEJMoa1113205 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ (2010) Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer 116(3):616–624. doi: 10.1002/cncr.24768 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fasso M, Wang YV, Zou W, Hegde PS, Fine GD, Powles T (2016) Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34(8):833–842. doi: 10.1200/JCO.2015.63.7421 CrossRefPubMedGoogle Scholar
  14. 14.
    Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D (2011) Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol 6:34. doi: 10.1186/1748-717X-6-34 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Teh B, Bloch C, Galli-Guevara M, Doh L, Richardson S, Chiang S, Yeh P, Gonzalez M, Lunn W, Marco R, Jac J, Paulino A, Lu H, Butler E, Amato R (2007) The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J 3(1):e6. doi: 10.2349/biij.3.1.e6 PubMedPubMedCentralGoogle Scholar
  16. 16.
    Dybal EJ, Haas GP, Maughan RL, Sud S, Pontes JE, Hillman GG (1992) Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. J Urol 148(4):1331–1337PubMedGoogle Scholar
  17. 17.
    Samlowski WE, Majer M, Boucher KM, Shrieve AF, Dechet C, Jensen RL, Shrieve DC (2008) Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer 113(9):2539–2548. doi: 10.1002/cncr.23857 CrossRefPubMedGoogle Scholar
  18. 18.
    Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, Miller W, Payne R, Glenn L, Bageac A, Urba WJ (2012) Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Sci Transl Med 4(137):137ra174. doi: 10.1126/scitranslmed.3003649 CrossRefGoogle Scholar
  19. 19.
    Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113(2):293–301. doi: 10.1002/cncr.23552 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Negrier S, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C, Escudier B, Groupe Francais dI (2005) Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. World J Urol 23(3):161–165. doi: 10.1007/s00345-004-0467-z CrossRefPubMedGoogle Scholar
  21. 21.
    Lentsch AB, Miller FN, Edwards MJ (1999) Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother 47(5):243–248CrossRefPubMedGoogle Scholar
  22. 22.
    Druey KM, Greipp PR (2010) Narrative review: the systemic capillary leak syndrome. Ann Intern Med 153(2):90–98. doi: 10.7326/0003-4819-153-2-201007200-00005 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T (2014) Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother 37(7):360–365. doi: 10.1097/CJI.0000000000000044 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF (2009) Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 32(2):181–185. doi: 10.1097/CJI.0b013e3181952b1d CrossRefPubMedGoogle Scholar
  25. 25.
    Carlo MI, Voss MH, Motzer RJ (2016) Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol 13(7):420–431. doi: 10.1038/nrurol.2016.103 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ji Young Lee
    • 1
  • Cheryn Song
    • 2
  • Bum Sik Hong
    • 2
  • Jun Hyuk Hong
    • 2
  • Hanjong Ahn
    • 2
  • Jae Lyun Lee
    • 1
    Email author
  1. 1.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  2. 2.Department of Urology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea

Personalised recommendations